Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension
Pulmonary Circulation · 2025-07 · 15 (3)
DOI: 10.1002/pul2.70132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 18.07.2025. Verfasst von Clara Hjalmarsson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Sahlgrenska University Hospital Gothenburg Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Evidence on the predictive ability of risk assessment models for event‐free survival (EFS) in patients with pulmonary arterial hypertension is scarce. We aimed to investigate the relationship between risk status at 6 months after diagnosis (6 M) and EFS, by three risk models: Multicomponent Improvement (MCI), ESC/ERS 4‐Strata Risk (4SR), and noninvasive French PH Registry Score (FRS). Data collected in the Swedish PAH Registry 2008–2021 were used. The study population was risk‐stratified at 6 M according to each model. Information on PAH‐related hospitalization (HOSP) was collected from the National Patient Register. EFS was defined as survival without occurrence of: (1) HOSP; (2) initiation of parenteral prostacyclin therapy or dose increase ≥ 10%; (3) lung transplantation. The association between risk and EFS was evaluated by Kaplan–Meier estimates and Cox proportional models. The analysis included 411 incident patients, median age 66 y [50, 73]. Median survival time was 3.5 y [1.7; 5.4], and cumulative EFS was 55%. In a Cox proportional regression adjusted for age, eGFR, obesity, atrial fibrillation, and systemic hypertension, EFS was higher in patients who: (1) achieved two or three MCI criteria compared to one or no MCI criterion (HR 0.58; CI 0.39–0.84, p = 0.005); (2) were assessed as low, intermediate–low, or intermediate–high compared to high risk (HR 0.16; CI 0.09–0.28, p < 0.001); or (3) fulfilled one, two, or three low‐risk FRS criteria, compared to no low‐risk criterion (HR 0.29; CI 0.19–0.43, p < 0.001). Performing a risk assessment 6 months after diagnosis effectively predicts the likelihood of EFS in the studied population, highlighting its prognostic value.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology Sahlgrenska University Hospital Gothenburg Sweden.
- Institute of Medicine at Sahlgrenska Academy University of Gothenburg Gothenburg Sweden.
- Value and Implementation Outcomes Research, Merck & Co. Inc. Rahway New Jersey USA.
- Department of Clinical Sciences Lund, Cardiology, Skåne University Hospital Lund University Lund Sweden.
- Department of Cardiology University Hospital Uppsala Uppsala Sweden.
- Pediatric Heart Center, The Queen Silvia Children's Hospital Sahlgrenska University Hospital Gothenburg Sweden.
ORCID-Profile: Clara Hjalmarsson, Håkan Wåhlander, Barbro Kjellström
Zitieren
APA
Hjalmarsson, C., Thakur, T., Rådegran, G., Björklund, E., Wåhlander, H., Nisell, M., Papageorgiou, J. M., Söderberg, S., Lautsch, D., & Kjellström, B. (2025). Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension. Pulmonary Circulation, 15(3). https://doi.org/10.1002/pul2.70132
Vancouver
Hjalmarsson C, Thakur T, Rådegran G, Björklund E, Wåhlander H, Nisell M, et al. Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension. Pulmonary Circulation. 2025;15(3). doi:10.1002/pul2.70132
BibTeX
@article{Hjalmarsson2025,
author = {Hjalmarsson, Clara and Thakur, Tanvee and Rådegran, Göran and Björklund, Erik and Wåhlander, Håkan and Nisell, Magnus and Papageorgiou, Joanna-Maria and Söderberg, Stefan and Lautsch, Dominik and Kjellström, Barbro},
title = {Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension},
journal = {Pulmonary Circulation},
year = {2025},
volume = {15},
number = {3},
doi = {10.1002/pul2.70132}
}
EUVIMED